Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Kuemmerle‐Deschner, Jasmin; Hachulla, É.; Cartwright, R.; Hawkins, Philip N.; Tran, Tú-Anh; Bader-Meunier, Brigitte; Hoyer, Joachim; Gattorno, Marco; Gül, Ahmet; Smith, Jacqueline Y. Channon; Leslie, Kieron; Jiménez, Santiago; Morell-Dubois, Sandrine; Davis, Nicole L.; Patel, Neha; Widmer, A.; Preiss, R.; Lachmann, HJ

doi:10.1136/ard.2011.152728

Cited by 197 publications

(185 citation statements)

References 22 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…Children with severe CAPS show manifestations of elevated intracranial pressure and are believed to be mentally slow or even retarded. However, both mental and hearing impairment are reversed on treatment with anakinra (23,102,104-107) but also with specific neutralization of IL-1β with canakinumab (103,(108)(109)(110)(111). Meniere disease can also be characterized by progressive sensorineural hearing loss and is also associated with dysregulation of IL-1β (98,99,112).…”

Section: Autoimmune Hearing Lossmentioning

confidence: 99%

See 1 more Smart Citation

An Expanding Role for Interleukin-1 Blockade from Gout to Cancer

Dinarello

2014

Mol Med

View full text Add to dashboard Cite

There is an expanding role for interleukin (IL)-1 in diseases from gout to cancer. More than any other cytokine family, the IL-1 family is closely linked to innate inflammatory and immune responses. This linkage is because the cytoplasmic segment of all members of the IL-1 family of receptors contains a domain, which is highly homologous to the cytoplasmic domains of all toll-like receptors (TLRs). This domain, termed "toll IL-1 receptor (TIR) domain," signals as does the IL-1 receptors; therefore, inflammation due to the TLR and the IL-1 families is nearly the same. Fundamental responses such as the induction of cyclo-oxygenase type 2, increased surface expression of cellular adhesion molecules and increased gene expression of a broad number of inflammatory molecules characterizes IL-1 signal transduction as it does for TLR agonists. IL-1β is the most studied member of the IL-1 family because of its role in mediating autoinflammatory disease. However, a role for IL-1α in disease is being validated because of the availability of a neutralizing monoclonal antibody to human IL-1α. There are presently three approved therapies for blocking IL-1 activity. Anakinra is a recombinant form of the naturally occurring IL-1 receptor antagonist, which binds to the IL-1 receptor and prevents the binding of IL-1β as well as IL-1α. Rilonacept is a soluble decoy receptor that neutralizes primarily IL-1β but also IL-1α. Canakinumab is a human monoclonal antibody that neutralizes only IL-1β. Thus, a causal or significant contributing role can be established for IL-1β and IL-1α in human disease.

show abstract

Section: Autoimmune Hearing Lossmentioning

confidence: 99%

“…In a study of CAPS patients, 54% had sensorineural deafness (101). Treatment with either anakinra or canakinumab resulted in a complete resolution of symptoms (101)(102)(103). Children with severe CAPS show manifestations of elevated intracranial pressure and are believed to be mentally slow or even retarded.…”

Section: Autoimmune Hearing Lossmentioning

confidence: 99%

An Expanding Role for Interleukin-1 Blockade from Gout to Cancer

Dinarello

2014

Mol Med

View full text Add to dashboard Cite

show abstract

“…Рандомизированные контролируемые исследования по применению канакинумаба у пациентов с CAPS немно-гочисленны [9,[20][21][22][23][24][25][26][27]. H. Lachmann с соавт.…”

Section: в практику педиатраunclassified

Case of Using the Inhibitor of Interleukin 1 Canacinumab in Patients with Auto Inflammatory Diseases

Салугина¹,

Федоров²,

Кузьмина³

et al. 2015

PPh

View full text Add to dashboard Cite

“…Since these three disorders involve a mutation in the NLRP3 gene, which regulates IL-1, the blockade of IL-1 is a common therapeutic option for all three conditions. 7,[11][12][13] Canakinumab, a monoclonal antibody targeted against IL-1beta, has been reported to have great efficacy with remission of symptoms in CAPS patients. 3,7 However, canakinumab can lead to intolerable dermatologic symptoms, as demonstrated by the rash patient 3 developed.…”

Section: Nlrp3 Gene Mutations Brief Reportsmentioning

confidence: 99%